QIAGEN and Protedyne Enter Collaboration to Develop Nucleic Acid Purification Solution for Ultra High-Throughput Molecular Diagn

14-Jun-2004

Venlo and Windsor QIAGEN and Protedyne Corporation, a premier supplier of industrial robotics for research, drug discovery and testing laboratories, announced that they have entered into a collaboration to develop a fully automated ultra high-throughput sample preparation system for molecular diagnostic customers. The collaboration is aimed at developing optimized ultra high-throughput nucleic acid purification procedures on Protedyne's BioCube Systems.

QIAGEN's proprietary nucleic acid sample preparation and handling technologies provide the highest reliability and efficiency in all preanalytical sample preparation steps, from sample collection to separation, purification and handling of DNA and RNA in molecular diagnostics. Protedyne Corporation brings industrial laboratory automation solutions to today's progressive biotechnology, diagnostics, and pharmaceutical companies.

Optimized protocols for ultra high-throughput diagnostic sample preparation which result from this collaboration will be described in technical notes to be made available by both companies.

"We are very pleased that Protedyne and QIAGEN have entered into a partnership," said Dr. Frank Krieg-Schneider, Director Strategic Alliances at QIAGEN. "The combination of Protedyne's ultra high-throughput automation systems with QIAGEN's preanalytical sample preparation technologies strengthens QIAGEN's already broad portfolio of automated sample preparation solutions for molecular diagnostics and clinical research in the fields of ultra high-throughput applications. We strongly believe that QIAGEN's technology and market leadership in preanalytical sample preparation is adding substantial value to the molecular diagnostics markets and will boost the development of standardized and highly efficient solutions in these emerging and rapidly growing markets."

"We are excited to extend our diagnostics application portfolio through this partnership with QIAGEN. The combination of proven purification chemistries and robust automation will greatly benefit ultra high throughput customers," says Greg Endress, Protedyne's Chief Scientific Officer. "Together they enable the quick processing of patient samples while maintaining integrity. It also permits the rapid movement of samples into a number of molecular diagnostic tests."

https://www.bionity.com/en/news/38014/qiagen-and-protedyne-enter-collaboration-to-develop-nucleic-acid-purification-solution-for-ultra-high-throughput-molecular-diagn.html